Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclooxygenase-2 inhibitors: what went wrong?

Michael J James1, Leslie G Cleland

  • 1Rheumatology Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia. mjames@mail.rah.sa.gov.au

Current Opinion in Clinical Nutrition and Metabolic Care
|February 16, 2006
PubMed
Summary

Selective cyclooxygenase-2 inhibitors (coxibs) were developed for improved gastrointestinal safety but showed increased cardiovascular risk. Despite evidence, widespread use continued, highlighting a failure in medical literature to guide drug safety.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of the complete pathway for conversion of bilirubin to urobilinogen by human gut bacteria.

bioRxiv : the preprint server for biology·2026
Same author

Reductive radical chain initiation through the thermal generation of carbon dioxide radical anion.

Nature synthesis·2026
Same author

Correction: Computational methods for investigating organic radical species.

Organic & biomolecular chemistry·2025
Same author

<i>Staphylococcus aureus</i> uses a GGDEF protein to recruit diacylglycerol kinase to the membrane for lipid recycling.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

PgpP is a broadly conserved phosphatase required for phosphatidylglycerol lipid synthesis.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

Nucleophilic Amination of Aryl Halides with an Azanide Surrogate.

Chemistry (Weinheim an der Bergstrasse, Germany)·2024

Area of Science:

  • Pharmacology
  • Drug Development
  • Cardiovascular Medicine

Background:

  • Selective cyclooxygenase-2 (COX-2) inhibitors, or coxibs, were designed to offer improved upper gastrointestinal safety over traditional non-selective NSAIDs.
  • The development was based on understanding the structural differences between COX-1 and COX-2 enzymes.

Purpose of the Study:

  • To review the biological basis for selective COX-2 inhibitor development.
  • To document the clinical experience, from initial gastrointestinal safety trials to subsequent cardiovascular safety concerns and drug withdrawals or warnings.

Main Methods:

  • Review of pivotal clinical trials evaluating gastrointestinal safety of coxibs.
  • Analysis of cardiovascular safety data emerging from large-scale studies and post-marketing surveillance.

Related Experiment Videos

  • Examination of biological mechanisms proposed for COX-2 inhibitor-associated cardiovascular risk.

    • Main Results:

    • While some coxibs showed improved upper gastrointestinal safety, celecoxib did not demonstrate superiority over non-selective NSAIDs in large trials.
    • Rofecoxib demonstrated improved upper gastrointestinal safety compared to naproxen, but clinical trial evidence of increased cardiovascular risk emerged.
    • Despite emerging cardiovascular risks and plausible biological mechanisms, coxibs were widely used for several years before further regulatory action.

    Conclusions:

    • The clinical events surrounding coxibs serve as a critical case study in the limitations of medical journal literature for effectively guiding drug usage and safety.
    • The widespread use of coxibs, despite conflicting safety data, underscores the challenges in translating scientific evidence into clinical practice and regulatory action.